Navigation Links
UC San Diego cancer scientist wins $3 million award
Date:2/20/2013

Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award.

The prize is the collaborative creation of Mark Zuckerberg, founder of Facebook, and his wife, Priscilla Chan; Sergey Brin, co-founder of Google and his wife, Anne Wojcicki, founder of the genetics company 23andMe; and Yuri Milner, a Russian businessman and philanthropist who established a similar prize in fundamental physics last year, when $3 million each was awarded to nine researchers.

The Breakthrough Prize honors life scientists who have ambitiously pushed the boundaries of their disciplines, taken risks and impacted lives and society.

Ferrara, who is also a distinguished professor of pathology in the UC San Diego School of Medicine's Department of Pathology, was recognized for his work identifying the role of the human VEGF gene in promoting angiogenesis the formation of new blood vessels that can feed tumor growth and subsequent development of two major monoclonal antibody drugs: Bevacizumab (marketed as Avastin), which is used to treat multiple forms of cancer, including breast, brain and colorectal, and ranibizumab (marketed as Lucentis), which treats wet age-related macular degeneration, a leading cause of blindness in the elderly.

"Napoleone's work has profoundly advanced our basic understanding of how cancer develops and grows," said David Brenner, MD, vice chancellor for Health Sciences and dean of the UC San Diego School of Medicine. "More importantly, he helped create brand new drugs and therapies based upon that research to effectively treat a broad range of cancers and other conditions. He continues with those efforts today, pushing himself and colleagues to find better answers to cancer."

Ferrara, 56, came to UC San Diego last year after a long career at Genentech, the San Francisco-based biotechnology company where he did much of his ground-breaking work. He said that when Breakthrough Prize Foundation president Arthur D. Levinson, chairman of Apple and a former Genentech chief executive, called to tell him he had won, he was "very much astonished. I didn't know the award existed."

"The thing I am most proud of," said Ferrara, "is that we've advanced the understanding of basic mechanisms of cancer and we've been able to help people, both in fighting cancer and restoring visual acuity. It's that kind of work that I'm continuing at Moores Cancer Center, where I'll be able to work closely with clinicians and develop new clinical trials."

Scott Lippman, MD, director of the UC San Diego Moores Cancer Center, said the Breakthrough Prize justly recognizes Ferrara's seminal research and how it "has changed therapy for cancer and eye diseases."

"His work epitomizes our overall effort at Moores Cancer Center: high-risk, high-gain, high-impact achievement and innovation in taking basic-science discovery to the clinic and transforming cancer care."

Joining Ferrara among the first winners of the Breakthrough Prize are:

  • Cornelia I. Bargmann, Rockefeller University, who studies the nervous system and human behavior
  • David Botstein, Princeton University, who uses the human genome to map disease biomarkers
  • Lewis C. Cantley, Weill Cornell Medical College, who discovered a family of enzymes related to cell and cancer growth
  • Hans Clevers, Hubrecht Institute in the Netherlands, who has parsed how stem cell processes go awry, resulting in cancer
  • Eric S. Lander, Harvard University and the Massachusetts Institute of Technology (MIT), a leader in the Human Genome Project
  • Titia de Lange, Rockefeller University, who studies the protective tips of chromosomes called telomeres
  • Charles L. Sawyer, Memorial Sloan-Kettering Cancer Center, who has investigated the signals that prompt a cell to become cancerous
  • Bert Vogelstein, Johns Hopkins University, who developed a model for how colon cancer progresses and discovered a protein that suppresses tumor growth
  • Robert A. Weinberg, MIT, who discovered the first human oncogene
  • Shinya Yamanaka, Kyoto University and Gladstone Institutes in San Francisco, for his fundamental research of stem cells

The founders of the Breakthrough Prize intend their awards which will consist of five honorees in subsequent years, each receiving $3 million to boost public attention and awareness of the major players and advances in the life sciences.

There are few limitations on who can win: Anyone can be nominated online at the Breakthrough Prize in Life Sciences Foundation's website. There are no restrictions on age or the number of people who can share the award. The cash prize comes with no constraints on how it can be spent. And individuals can win multiple times. This year's 11 recipients will form a committee to select future winners.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. UC San Diego Superfund Research Program receives $15 million grant renewal
2. UC San Diego researchers receive new CIRM funding
3. San Diego Physician to be Recognized at White House for Progress in Health IT
4. Tragic San Diego Dog Attack Leaves One Infant Dead – California Dog Bite Attorneys Revive Pit Bull Warnings
5. UC San Diego, Yale awarded collaborative NSF grant for Neuroscience Gateway
6. Join GSA in San Diego for the Nations Premier Aging Conference!
7. Register now! San Diego meeting will showcase latest aging discoveries
8. Shaft Medical San Diego now offers micro needle sclerotherapy to treat scary “spider” veins.
9. Shaft Medical San Diego Now Offers Viridis Derma KTP Laser to Permanently Remove Unwanted Spider Veins
10. Massage School San Diego Releases Raw Food Holiday Ideas
11. Continuing education provider HomeCEUConnection.com Announces Upcoming Attendance at Annual American Physical Therapy Association Combined Sections Meeting in San Diego.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC San Diego cancer scientist wins $3 million award
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted ... ARRS Art Forum held recently at the Annual Meeting in Los Angeles. The first ... ARRS members and Annual Meeting attendees. , “Through art I hope to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent ... pet gear and toys, leading product review site for Toys, Tots, Pets & More ... at their Spring Showcase at the Metropolitan Pavilion in New York City. , ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... has announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty ... the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for Disease ... of 18. Of those who survive, many still face effects as they reach adulthood. ... new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who are ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
Breaking Medicine Technology: